Tom A BÃ¤ck

List of Publications by Year
in descending order

38 papers	1,476 citations	304743 22 h-index	315739 38 g-index
38 all docs	38 docs citations	38 times ranked	1011 citing authors

#	ARTICLE	IF	CITATIONS
1	Evaluation of therapeutic efficacy of 211At-labeled farletuzumab in an intraperitoneal mouse model of disseminated ovarian cancer. Translational Oncology, 2021, 14, 100873.	3.7	9
2	Radium-223â€“Induced Bystander Effects Cause DNA Damage and Apoptosis in Disseminated Tumor Cells in Bone Marrow. Molecular Cancer Research, 2021, 19, 1739-1750.	3.4	13
3	Modeling bystander effects that cause growth delay of breast cancer xenografts in bone marrow of mice treated with radium-223. International Journal of Radiation Biology, 2021, 97, 1217-1228.	1.8	6
4	Surface Adsorption of the Alpha-Emitter Astatine-211 to Gold Nanoparticles Is Stable In Vivo and Potentially Useful in Radionuclide Therapy. Journal of Nanotheranostics, 2021, 2, 196-207.	3.1	4
5	Dose-Dependent Growth Delay of Breast Cancer Xenografts in the Bone Marrow of Mice Treated with²²³Ra: The Role of Bystander Effects and Their Potential for Therapy. Journal of Nuclear Medicine, 2020, 61, 89-95.	5.0	34
6	Realizing Clinical Trials with Astatine-211: The Chemistry Infrastructure. Cancer Biotherapy and Radiopharmaceuticals, 2020, 35, 425-436.	1.0	41
7	Targeted alpha therapy with astatine-211-labeled anti-PSCA A11 minibody shows antitumor efficacy in prostate cancer xenografts and bone microtumors. EJNMMI Research, 2020, 10, 10.	2.5	16
8	Labeling of Anti-HER2 Nanobodies with Astatine-211: Optimization and the Effect of Different Coupling Reagents on Their in Vivo Behavior. Molecular Pharmaceutics, 2019, 16, 3524-3533.	4.6	42
9	Intraperitoneal Î±-Emitting Radioimmunotherapy with ²¹¹At in Relapsed Ovarian Cancer: Long-Term Follow-up with Individual Absorbed Dose Estimations. Journal of Nuclear Medicine, 2019, 60, 1073-1079.	5.0	53
10	Model of Intraperitoneal Targeted Î±-Particle Therapy Shows That Posttherapy Cold-Antibody Boost Enhances Microtumor Radiation Dose and Treatable Tumor Sizes. Journal of Nuclear Medicine, 2018, 59, 646-651.	5.0	8
11	Therapeutic efficacy of Î±-radioimmunotherapy with different activity levels of the 213Bi-labeled monoclonal antibody MX35 in an ovarian cancer model. EJNMMI Research, 2017, 7, 38.	2.5	15
12	Immunohistochemical evaluation of epithelial ovarian carcinomas identifies three different expression patterns of the MX35 antigen, NaPi2b. BMC Cancer, 2017, 17, 303.	2.6	30
13	Cure of Human Ovarian Carcinoma Solid Xenografts by Fractionated Î±-Radioimmunotherapy with ²¹¹At-MX35-F(abâ€²)₂: Influence of Absorbed Tumor Dose and Effect on Long-Term Survival. Journal of Nuclear Medicine, 2017, 58, 598-604.	5.0	16
14	Pharmacokinetics, microscale distribution, and dosimetry of alpha-emitter-labeled anti-PD-L1 antibodies in an immune competent transgenic breast cancer model. EJNMMI Research, 2017, 7, 57.	2.5	35
15	Biokinetic Modeling and Dosimetry for Optimizing Intraperitoneal Radioimmunotherapy of Ovarian Cancer Microtumors. Journal of Nuclear Medicine, 2016, 57, 594-600.	5.0	18
16	Synthesis and Evaluation of Astatinated <i>N</i>-[2-(Maleimido)ethyl]-3-(trimethylstannyl)benzamide Immunoconjugates. Bioconjugate Chemistry, 2016, 27, 688-697.	3.6	20
17	Astatine-211 conjugated to an anti-CD20 monoclonal antibody eradicates disseminated B-cell lymphoma in a mouse model. Blood, 2015, 125, 2111-2119.	1.4	52
18	Binding Affinity, Specificity and Comparative Biodistribution of the Parental Murine Monoclonal Antibody MX35 (Anti-NaPi2b) and Its Humanized Version Rebmab200. PLoS ONE, 2015, 10, e0126298.	2.5	19

#	Article	IF	Citations
19	Î±-Imaging Confirmed Efficient Targeting of CD45-Positive Cells After ²¹¹At-Radioimmunotherapy for Hematopoietic Cell Transplantation. Journal of Nuclear Medicine, 2015, 56, 1766-1773.	5.0	18
20	Absorbed Doses and Risk Estimates of 211At-MX35 F(ab')2 in Intraperitoneal Therapy of Ovarian Cancer Patients. International Journal of Radiation Oncology Biology Physics, 2015, 93, 569-576.	0.8	45
21	Automated astatination of biomolecules â€“ a stepping stone towards multicenter clinical trials. Scientific Reports, 2015, 5, 12025.	3.3	29
22	Alpha particle induced DNA damage and repair in normal cultured thyrocytes of different proliferation status. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2014, 765, 48-56.	1.0	7
23	Comparison of ²¹¹At-PRIT and ²¹¹At-RIT of Ovarian Microtumors in a Nude Mouse Model. Cancer Biotherapy and Radiopharmaceuticals, 2013, 28, 108-114.	1.0	21
24	Ex Vivo Activity Quantification in Micrometastases at the Cellular Scale Using the Î±-Camera Technique. Journal of Nuclear Medicine, 2013, 54, 1347-1353.	5.0	24
25	Anti-CD45 radioimmunotherapy using 211At with bone marrow transplantation prolongs survival in a disseminated murine leukemia model. Blood, 2013, 121, 3759-3767.	1.4	59
26	Evaluation of Effects on the Peritoneum After Intraperitoneal Î±-Radioimmunotherapy with²¹¹At. Cancer Biotherapy and Radiopharmaceuticals, 2012, 27, 353-364.	1.0	13
27	Comparison of therapeutic efficacy and biodistribution of 213Bi- and 211At-labeled monoclonal antibody MX35 in an ovarian cancer model. Nuclear Medicine and Biology, 2012, 39, 15-22.	0.6	32
28	Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: high rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft model. Blood, 2011, 118, 703-711.	1.4	48
29	In Vivo Distribution of Avidin-Conjugated MX35 and 211At-Labeled, Biotinylated Poly-l-Lysine for Pretargeted Intraperitoneal Î±-Radioimmunotherapy. Cancer Biotherapy and Radiopharmaceuticals, 2011, 26, 727-736.	1.0	10
30	Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease. Blood, 2010, 116, 4231-4239.	1.4	63
31	The Î±-Camera: A Quantitative Digital Autoradiography Technique Using a Charge-Coupled Device for Ex Vivo High-Resolution Bioimaging of Î±-Particles. Journal of Nuclear Medicine, 2010, 51, 1616-1623.	5.0	97
32	Intraperitoneal Î±-Particle Radioimmunotherapy of Ovarian Cancer Patients: Pharmacokinetics and Dosimetry of ²¹¹At-MX35 F(abâ€²)₂â€”A Phase I Study. Journal of Nuclear Medicine, 2009, 50, 1153-1160.	5.0	245
33	Glomerular Filtration Rate After Alpha-Radioimmunotherapy with²¹¹At-MX35-F(abâ€²)₂: A Long-Term Study of Renal Function in Nude Mice. Cancer Biotherapy and Radiopharmaceuticals, 2009, 24, 649-658.	1.0	29
34	Direct Procedure for the Production of²¹¹At-Labeled Antibodies with an Îµ-Lysyl-3-(Trimethylstannyl)Benzamide Immunoconjugate. Journal of Nuclear Medicine, 2008, 49, 1537-1545.	5.0	60
35	Alpha-radioimmunotherapy of intraperitoneally growing OVCAR-3 tumors of variable dimensions: Outcome related to measured tumor size and mean absorbed dose. Journal of Nuclear Medicine, 2006, 47, 1342-50.	5.0	43
36	Therapeutic efficacy and tumor dose estimations in radioimmunotherapy of intraperitoneally growing OVCAR-3 cells in nude mice with (211)At-labeled monoclonal antibody MX35. Journal of Nuclear Medicine, 2005, 46, 1907-15.	5.0	49

#	Article	IF	Citations
37	211At radioimmunotherapy of subcutaneous human ovarian cancer xenografts: evaluation of relative biologic effectiveness of an alpha-emitter in vivo. Journal of Nuclear Medicine, 2005, 46, 2061-7.	5.0	29
38	Dry-distillation of astatine-211 from irradiated bismuth targets: a time-saving procedure with high recovery yields. Applied Radiation and Isotopes, 2001, 55, 157-160.	1.5	124